Remove Genome Remove Genomics Remove Medicine Remove Research
article thumbnail

Hopewell Therapeutics raises funds for genomic medicines development

Pharmaceutical Technology

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130
article thumbnail

How 3D genomics can accelerate personalised medicine

Drug Discovery World

Dr Daniel Turner, Chief Scientific Officer, Enhanc3D Genomics, outlines how 3D genomics offers a radically novel approach to address challenges in drug target discovery and how it can affect change in drug target identification, cell therapy and personalised medicine.

Genome 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

‘100 Million Cell Challenge’ to boost single cell genomics research

Drug Discovery World

Scale Biosciences (Scale Bio) has launched the ‘100 Million Cell Challenge’, which hopes to push the boundaries of single-cell genomics research, in collaboration with Ultima Genomics and NVIDIA. Researchers interested in participating can submit their project proposals from 8 August to 15 October 2024.

Genome 59
article thumbnail

How Will Ultima Genomics and Genome Insight Make WGS Affordable?

XTalks

The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.

Genome 97
article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 104
article thumbnail

What are the key trends in genomics and precision medicine for 2024?

Drug Discovery World

Leading experts in genomics, personalised medicine and drug discovery convened at the Precision Medicine Community Event in London to unveil the latest advancements shaping the future of healthcare. The post What are the key trends in genomics and precision medicine for 2024?

Genome 59
article thumbnail

Eurofins Genomics and Olink partner to advance proteomics research

Drug Discovery World

Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes. The collaboration is designed to bolster the company’s offerings in the fields of research, population health, and regulated clinical trials. To read this content in full, you need to login.

Genome 59